# Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

> **NCT03718286** · PHASE2 · COMPLETED · sponsor: **Population Health Research Institute** · enrollment: 97 (actual)

## Conditions studied

- ST Elevation Myocardial Infarction
- Acute Coronary Syndrome
- Hypercholesterolemia
- Hyperlipidemias
- Dyslipidemias
- Physiological Effects of Drugs

## Interventions

- **DRUG:** Alirocumab
- **OTHER:** Sham Control

## Key facts

- **NCT ID:** NCT03718286
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-10-08
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718286, "Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03718286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*